A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...

In the next in our series, GP Dr Roger Henderson debunks common myths about prostate cancer – and highlights some less ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

Prostate cancer cells usually require male androgen hormones, such as testosterone, to grow. Androgen deprivation therapy ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including ...

When prostate cancer metastasizes, spreads outside of the prostate itself, it typically affects the structures in its immediate vicinity. Structures near the prostate likely to be involved include ...

Nuvation Bio Inc. , a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access Program (EAP) for taletrectinib in the ...

So when we talk about targeted therapies now, we're thinking of, for example, resistance pathways in prostate cancer, and PSMA is one of those. DNA damage repair pathways are also another ...

So obviously these are all hot topics within the broader field of cancer therapy, but I think that they will be used in prostate cancer in particular because we have good targets in prostate cancer.

The safety and short-term efficacy of neoadjuvant chemotherapy in elderly patients with resectable locally advanced esophageal squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ...